ebulized Furosemide and spirometric indexes in Chronic Obstructive Pulmonary Disease exacerbatio
Phase 3
Recruiting
- Conditions
- Chronic obstructive pulmonary disease exacerbation.Chronic obstructive pulmonary disease with (acute) exacerbation
- Registration Number
- IRCT20190109042305N1
- Lead Sponsor
- Sari University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 47
Inclusion Criteria
COPD exacerbation patients
FEV1/FVC less than 70%
No need for ventilator
Exclusion Criteria
FEV1 Increase greater than 200 cc or 12% after salbutamol administration in spirometry
The history of infectious diseases such as tuberculosis, recent respiratory infections, bronchiectasis and acute or chronic diarrhea
Probability of malignancy based on examination
Rheumatic arthritis, degenerative joint disease, vasculitis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Forced expiratory volume in 1 second (FEV1). Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.;Forced vital capacity. Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.
- Secondary Outcome Measures
Name Time Method Peak Expiratory Flow Rate. Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.;Severity of respiratory distress. Timepoint: Before prescribing medications, as well as 30 minutes and one hour after administration. Method of measurement: Accessory muscle score.;Adverse effect. Timepoint: Before prescribing medications, as well as 30 minutes and one hour after administration. Method of measurement: Patient evaluation.